Key result
Beta-blockers linked to ~35% lower all-cause mortality, while ACEi/ARBs, statins, and aspirin show no benefit.
Why the study?
The efficacy of secondary prevention medical therapy for reducing all-cause mortality in patients with takotsubo cardiomyopathy is not well established.
Does secondary prevention medical therapy reduce all-cause mortality in patients with Takotsubo cardiomyopathy?
Meta-Analysis (n=9,237)
Does secondary prevention medical therapy reduce all-cause mortality in patients with Takotsubo cardiomyopathy?
In a network meta-analysis of observational studies, beta-blockers were associated with a significant reduction in all-cause mortality in patients with Takotsubo cardiomyopathy, whereas other secondary prevention medications were not.
Answers are grounded in this paper and cite their sources.
May inform beta-blocker use in Takotsubo cardiomyopathy; leaves open randomized confirmation for secondary prevention.
Aims: Takotsubo cardiomyopathy (TTC) is a form of transient left ventricular systolic dysfunction without evidence of complicated coronary artery disease. Efficacy of medical therapy in secondary prevention of all-cause mortality is not well established. We performed a systematic review and network meta-analysis to compare survival benefit of secondary prevention medical therapy in patients with TTC. Methods and results: PubMed, Embase, and Cochrane were searched up to 6 January 2024. Eligible studies included multivariable-adjusted or propensity-matched studies of patients receiving medical therapy with beta-blockers, angiotensin-converting enzyme inhibitors (ACE) or angiotensin receptor blockers (ARBs), aspirin, and statins after an index presentation with TTC. The primary outcome was all-cause mortality at any time point. Secondary outcome was TTC recurrence. Random-effect hierarchical Bayesian meta-analysis was performed. We identified 13 observational studies. Takotsubo cardiomyopathy mortality was reported in 435 (4.7%) out of 9237 patients, across a median follow-up of 2.18 years. Mean age was 69.7 ± 12.5 years, and 7906 patients (90.7%) were females. Beta-blockers were associated with a statistically significant reduction in mortality compared to control [hazard ratio (HR) 0.65, 95% confidence interval (CI) (0.55-0.77)]. ACE inhibitors/ARBs showed a nonsignificant trend towards mortality reduction [HR 0.76, 95% CI (0.54-1.07)]. Statins [HR 0.96, 95% CI (0.77-1.19)] and aspirin [HR 0.87, 95% CI (0.55-1.38)] showed no significant mortality benefit. Bayesian probability ranks favoured beta-blockers as the most effective treatment for TTC mortality prevention. Conclusion: This review highlights the modest efficacy of secondary prevention medications in the management of TTC, as ACE or ARBs, beta-blockers, aspirin, and statins failed to demonstrate comparative mortality benefit. Randomized controlled trials are needed to confirm efficacy of pharmacotherapy in this vulnerable patient cohort.
No takes yet. Share an insight, caveat, or question.
Mutahar et al. (2025) conducted a meta-analysis in Takotsubo cardiomyopathy (n=9,237). Secondary prevention medical therapy (beta-blockers, ACE inhibitors/ARBs, statins, aspirin) vs. Control was evaluated on All-cause mortality at any time point (HR 0.65, 95% CI 0.55-0.77). Beta-blockers were associated with a significant reduction in all-cause mortality, whereas ACE inhibitors/ARBs, statins, and aspirin showed no significant benefit.
Synapse has enriched 10 related papers. Consider them for comparative context: